Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albinterferon alfa-2b Fusion Protein in Hepatitis B Patients
NCT03294798Phase 2Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Jun 2017
- Primary completion
- Mar 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of albinterferon alfa-2b in hepatitis B (HBV), sponsored by CanSino Biologics Inc.. Started Jun 2017; status: completed.
02
Drugs
albinterferon alfa-2b
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03294798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03294798.